New Evidence on GLP‑1 and SGLT‑2 Therapies for Weight Management

A review of clinical trials compared two drug classes for weight management: GLP‑1 receptor agonists and SGLT‑2 inhibitors. Both improved weight, blood sugar, and blood pressure versus placebo. GLP‑1 drugs were best at lowering blood sugar and one GLP‑1 stood out for the biggest weight and metabolic gains, but it had higher rates of adverse effects. SGLT‑2 inhibitors were less potent but better tolerated. Choice of therapy should weigh efficacy against side‑effect risk.

Source : https://pubmed.ncbi.nlm.nih.gov/36882248/